Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 9/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127646 | 0.86 | POLB (0.35) | SIGMAR1ALDH1A1DDB1CRBN | |
| SCHEMBL22127648 | 0.86 | POLB (0.35) | SIGMAR1ALDH1A1DDB1CRBN | |
| SCHEMBL22127490 | 0.80 | NPC1L1 (0.36) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL17858904 | 0.80 | NPC1L1 (0.38) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL22127489 | 0.80 | NPC1L1 (0.36) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL29607523 | 0.80 | KDM4E (0.38) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL17858977 | 0.80 | NPFFR1 (0.37) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL22147799 | 0.79 | NOS1 (0.38) | SIGMAR1ALDH1A1DDB1CRBN | |
| SCHEMBL22127477 | 0.78 | NPC1L1 (0.37) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E | |
| SCHEMBL22127476 | 0.78 | NPC1L1 (0.37) | NPC1L1SIGMAR1NPFFR1NPFFR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-07 | — | — | US | disclosed |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | NPC1L1 3727/4885SIGMAR1 2772/4885NPFFR1 3788/4885 |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | NPC1L1 3727/4885SIGMAR1 2772/4885NPFFR1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.